Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series.
ballooning
metabolic syndrome
pathological definition
prognosis
steatohepatitic hepatocellular carcinoma
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
29
03
2023
received:
15
02
2023
accepted:
01
05
2023
medline:
13
9
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
ppublish
Résumé
According to the last WHO classification, steatohepatitic hepatocellular carcinoma (SH-HCC) is recognized as a distinct HCC subtype, even though a consensual definition is still lacking. The objectives of the study were to carefully describe the morphological features of SH-HCC and evaluate its impact on prognosis. We conducted a single-centre retrospective study including 297 surgically resected HCC. Pathological features including SH criteria (steatosis, ballooning, Mallory-Denk bodies, fibrosis, and inflammation) were assessed. SH-HCC was defined by the presence of at least four of the five SH criteria and the SH component represented >50% of the tumour area. According to this definition, 39 (13%) HCC cases corresponded to SH-HCC and 30 cases (10%) corresponded to HCC with an SH component (<50%). SH criteria in SH-HCC and non-SH-HCC were distributed as follows: ballooning (100% versus 11%), fibrosis (100% versus 81%), inflammation (100% versus 67%), steatosis (92% versus 8%), and Mallory-Denk bodies (74% versus 3%). Inflammation markers (c-reactive protein [CRP] and serum amyloid A [SAA]) were significantly more expressed in SH-HCC compared to non-SH-HCC (82% versus 14%, P = <0.001). Five-year recurrence-free survival (RFS) and 5-year overall survival (OS) were similar for SH-HCC and non-SH-HCC (P = 0.413 and P = 0.866, respectively). The percentage of SH component does not impact OS and RFS. We confirm in a large cohort the relatively high prevalence (13%) of SH-HCC. Ballooning is the most specific criteria for this subtype. The percentage of the SH component does not impact prognosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
526-537Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68; 394-424.
Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis. Front. Oncol. 2020; 10; 10.
Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140; 124-131.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59; 2188-2195.
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu. Rev. Med. 2016; 67; 103-117.
Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51; 1972-1978.
Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum. Pathol. 2012; 43; 737-746.
Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch. Pathol. Lab. Med. 2013; 137; 961-966.
Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M. Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 2014; 64; 951-962.
Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): A distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am. J. Surg. Pathol. 2010; 34; 1630-1636.
Digestive System Tumours. 5th edition - Who Classification of Tumours. Accessed March 6, 2021. https://www.livres-medicaux.com/who-classification-of-tumours-digestive-system-tumours-fifth-edition.html.
Aykutlu U, Argon A, Orman M et al. Steatotic and Steatohepatitic hepatocellular carcinomas: Features in a series with predominantly viral etiology. Am. J. Surg. Pathol. 2021; 45; 1252-1263. https://doi.org/10.1097/PAS.0000000000001714.
Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study. J. Gastroenterol. Hepatol. 2013; 28; 848-854.
Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J. Hepatol. 2019; 71; 616-630.
Boyault S, Rickman DS, de Reyniès A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45; 42-52.
Calderaro J, Couchy G, Imbeaud S et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol. 2017; 67; 727-738.
Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015; 149; 1226-1239.e4.
Fujiwara N, Nakagawa H, Enooku K et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 2018; 67; 1493-1504.
Van Treeck BJ, Mounajjed T, Moreira RK et al. Transcriptomic and proteomic analysis of Steatohepatitic hepatocellular carcinoma reveals novel distinct biologic features. Am. J. Clin. Pathol. 2021; 155; 87-96.
Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet. Med. 2006; 23; 469-480.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24; 289-293.
Bedossa P, Poitou C, Veyrie N et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56; 1751-1759.
Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41; 1313-1321.
Ziol M, Poté N, Amaddeo G et al. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018; 68; 103-112.
Calderaro J, Rousseau B, Amaddeo G et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology 2016; 64; 2038-2046.
Montasser A, Beaufrère A, Cauchy F et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021; 79; 36-46.
Qin J, Higashi T, Nakagawa S et al. Steatohepatitic variant of hepatocellular carcinoma is associated with both alcoholic steatohepatitis and nonalcoholic steatohepatitis: A study of 2 cohorts with molecular insights. Am. J. Surg. Pathol. 2020; 44; 1406-1412.
Olofson AM, Gonzalo DH, Chang M, Liu X. Steatohepatitic variant of hepatocellular carcinoma: a focused review. Gastroenterology Res. 2018; 11; 391-396.
Taniai M, Hashimoto E, Tobari M et al. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: A multicenter study using immunohistochemical analysis of adenoma-related markers. Hepatol. Res. 2018; 48; 947-955.
Deniz K, Moreira RK, Yeh MM, Ferrell LD. Steatohepatitis-like changes in focal nodular hyperplasia, a finding to distinguish from steatohepatitic variant of hepatocellular carcinoma. Am. J. Surg. Pathol. 2017; 41; 277-281.
Beaufrère A, Paradis V. Hepatocellular adenomas: review of pathological and molecular features. Hum. Pathol. 2021; 112; 128-137.
Inui S, Kondo H, Tanahashi Y et al. Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation. Clin. Radiol. 2021; 76; 160.e15-160.e25.
CT/MRI LI-RADS v2018. Accessed July 28, 2021. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018.
Cannella R, Burgio MD, Beaufrère A et al. Imaging features of histological subtypes of hepatocellular carcinoma: implication for LI-RADS. JHEPReport 2021; 3; 100380.